Comparative Pharmacology
Head-to-head clinical analysis: ATIVAN versus LIMBITROL DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATIVAN versus LIMBITROL DS.
ATIVAN vs LIMBITROL DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Limbitrol DS is a combination of amitriptyline (a tricyclic antidepressant) and chlordiazepoxide (a benzodiazepine). Amitriptyline inhibits the reuptake of serotonin and norepinephrine, enhancing neurotransmission in the CNS. Chlordiazepoxide binds to GABA-A receptors, potentiating GABAergic inhibitory effects, leading to anxiolytic and sedative effects.
2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.
1 tablet (amitriptyline 25 mg/chlordiazepoxide 10 mg) orally 3 times daily initially, gradually increasing to 2 tablets orally 3 times daily or 3 tablets orally twice daily if needed; maximum 6 tablets per day.
None Documented
None Documented
Terminal elimination half-life is 12–18 hours (mean ~14 h). In elderly, hepatic impairment, or obesity, half-life may be prolonged up to 30 hours.
Chlordiazepoxide: 5-30 hours (parent drug), active metabolite (desmethylchlordiazepoxide) 10-30 hours; amitriptyline: 13-36 hours (parent), nortriptyline (active metabolite) 18-44 hours. Half-lives increase with age and hepatic impairment.
Renal: lorazepam is primarily excreted as inactive glucuronide conjugates; <1% is excreted unchanged. Total: ~95% excreted in urine, ~5% in feces.
Renal: 70-80% as conjugated metabolites, <5% unchanged; fecal: 10-20% via biliary excretion.
Category C
Category C
Benzodiazepine
Benzodiazepine/Tricyclic Antidepressant Combination